322405-73-2

Upstream product

• 100-51-6 benzyl alcohol 
• 5774-77-6 2-(benzyloxy)acetamide 
• 32122-09-1 ethyl benzyloxyacetate 
• 13620-31-0 benzyloxyacetonitrile 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 322405-72-1 2-(benzyloxy)-1-(2,4,6-trihydroxyphenyl)ethanone 
• 108-73-6 3,5-dihydroxyphenol 

Downstream Products

• 322405-76-5 4-azido-benzoic acid 2-benzyloxyacetyl-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-phenyl ester 
• 322405-74-3 3-benzoyl-benzoic acid 2-benzyloxyacetyl-3,5-bis-(tert-butyl-diphenyl-silanyloxy)-phenyl ester 
• 636559-68-7 C₆₃H₆₆O₇Si₃ 
• 1104336-75-5 C₆₃H₆₄O₆Si₃ 
• 1104334-73-7 C₇₀H₇₀O₆Si₃ 
• 636559-67-6 C₇₀H₇₂O₇Si₃ 
• 322405-75-4 2-(3-benzoyl-phenyl)-3-benzyloxy-5-(tert-butyl-diphenyl-silanyloxy)-7-hydroxy-chromen-4-one 
• 322405-77-6 2-(4-azido-phenyl)-3-benzyloxy-5,7-dihydroxy-chromen-4-one 

Relevant academic research and scientific papers

Synthesis of flavonol derivatives as probes of biological processes

Two synthetic derivatives of the flavonol kaempferol were prepared in order to probe the biological mechanism of action of this natural product. Efficient synthetic routes to both a benzophenone-containing derivative and an amine-containing derivative are reported herein. (C) 2000 Elsevier Science Ltd.

RSK INHIBITORS AND THERAPEUTIC USES THEREOF

The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines while having little effect on the proliferation rate of normal cells. Therefore, the present invention identifies Rsk as a target for therapeutic intervention in diseased states in which the disease or the symptoms can be ameliorated by inhibition of Rsk catalytic activity.